Antiepileptic drug (AED) discontinuation after surgery is a very polarizing issue. The driving forces on either end of the debate are obvious: discontinuing AEDs could eliminate unnecessary side effects, improve quality of life, and reduce cost, while maintaining AEDs could avoid potential risks of breakthrough seizures and their untoward consequences. Every epileptologist “believes” in an ideal candidate population, in a best time to initiate AED withdrawal—if at all—and in an optimal rate of medication tapering. Every “believer” can provide logical reasons supporting his/her stance. But, like every “belief,” the current practice of postoperative medication management is closer to faith and personal experience than it is based on solid evidence. Multiple retrospective series are available (1–7), but few prospective studies have attempted to evaluate this issue, and both were observational (8, 9). In this “evidence-scarce” environment, what do we know?

First, several retrospective studies suggest an increased rate of seizure-recurrence with earlier postoperative AED withdrawal (3, 6–7): when “earlier” was defined as less than 6 months (3) or 9 months (7) after surgery, the rate of seizure recurrence was an absolute 15 to 20 percent higher in the earlier withdrawal category. The article by Boshuisen et al. chosen for this commentary further quantifies this hazard to an additional 5% recurrence risk for every 3 months reduction in the time interval from surgery to the start of AED withdrawal. Yet, the two prospective series do not necessarily support this concern, as one found similar relapse rates between patients who continued their AEDs and those who reduced them either from two to one AED or from one to no AED (8). The other reported on the rates of seizure recurrence after AED taper initiated at 3

---

**Commentary**

Antiepileptic drug (AED) discontinuation after surgery is a very polarizing issue. The driving forces on either end of the debate are obvious: discontinuing AEDs could eliminate unnecessary side effects, improve quality of life, and reduce cost, while maintaining AEDs could avoid potential risks of breakthrough seizures and their untoward consequences. Every epileptologist “believes” in an ideal candidate population, in a best time to initiate AED withdrawal—if at all—and in an optimal rate of medication tapering. Every “believer” can provide logical reasons supporting his/her stance. But, like every “belief,” the current practice of postoperative medication management is closer to faith and personal experience than it is based on solid evidence. Multiple retrospective series are available (1–7), but few prospective studies have attempted to evaluate this issue, and both were observational (8, 9). In this “evidence-scarce” environment, what do we know?

First, several retrospective studies suggest an increased rate of seizure-recurrence with earlier postoperative AED withdrawal (3, 6–7): when “earlier” was defined as less than 6 months (3) or 9 months (7) after surgery, the rate of seizure recurrence was an absolute 15 to 20 percent higher in the earlier withdrawal category. The article by Boshuisen et al. chosen for this commentary further quantifies this hazard to an additional 5% recurrence risk for every 3 months reduction in the time interval from surgery to the start of AED withdrawal. Yet, the two prospective series do not necessarily support this concern, as one found similar relapse rates between patients who continued their AEDs and those who reduced them either from two to one AED or from one to no AED (8). The other reported on the rates of seizure recurrence after AED taper initiated at 3
months or 1 year after surgery, with an eventual rate of seizure recurrence similar to historical controls (9). So, the debate about the immediate implications of AED withdrawal on seizure control can continue.

Second, most studies agree that seizure recurrences starting in the setting of AED withdrawal are easier to control than unprovoked postoperative seizure relapses (10). In Boshuisen et al., 70% of patients whose seizures started with AED reduction or discontinuation eventually regained seizure control, in concordance with prior data reporting remission rates of 50 to 66 percent in this scenario (7, 8, 10). While definitely encouraging, here are the issues with these numbers: 1) the significance of a 30% risk of being unable to regain seizure control after stopping AEDs is different for a child facing the prospect of a lifetime of cognitive and other medication side effects versus an adult who has finally regained independence, driving privileges, and a chance for meaningful employment; 2) it remains difficult to counsel an individual patient about the potential consequences of an AED withdrawal seizure because we don’t really know how easy or difficult it will be to re-achieve seizure control even if he/she is among the lucky 70% (i.e., is this control achieved over weeks or months, by returning to the preoperative AED regimen or necessitating additional AEDs).

Third, none of the studies to date demonstrated any negative long-term implications on seizure outcomes in patients who attempted AED withdrawal. While earlier studies found similar long-term seizure outcomes in patients whose medications were withdrawn compared with those who continued their AEDs (8), Boshuisen et al. further show here that these long-term seizure outcomes were independent of the time to start or complete AED withdrawal.

The overarching suggestion from all these findings is that withdrawing AEDs may uncover an incomplete resection of the epileptic focus (or possibly a resection that converted epilepsy from a pharmacoresistant to a pharmacoresponsive disease) without damaging the patient’s long-term prospects at seizure-freedom, no matter how early this withdrawal challenge is attempted. In other words, AED withdrawal may be to postsurgical epilepsy what a cardiac “stress test” is to coronary artery disease: rather than “causing” myocardial infarction, it serves to screen for its underlying pathology and to identify it early. If correct, this hypothesis would limit the uncertainty about whether, when, and how to withdraw AEDs after successful surgery, and would actually be a welcome tool to confirm who was cured with surgery and who needs to continue medical therapy. In reality, however, despite all the knowledge and hypotheses summarized above, the clinical practice of postoperative AED management hasn’t changed much over the past 2 decades (11, 12). Why? Because no matter how attractive the “stress test” hypothesis is, and how much circumstantial evidence supports it, it remains essentially unproven. Let’s revisit the evidence and discuss the challenges.

First, seizures recur after surgery, whether patients are taking AEDs or not. In fact, less than 20% of all postoperative seizure recurrences start in the setting of AED withdrawal (10). Second, approximately half of all postoperative seizure recurrences manifest first within 6 months after surgery, with slower subsequent rates of seizure recurrences such that any patient, whether on AEDs or not, will have higher rates of subsequent seizure recurrences earlier after surgery than any patient (on or off AEDs) who has already achieved a longer period of remission. Taken together, these two facts highlight the fine line between association and causality and represent the main limitation of drawing any “alarming” conclusions on the immediate implications of AED withdrawal on seizure control using the retrospective or observational prospective data currently available: we don’t really know how many of the seizure recurrences occurring after early or late AED withdrawal would have happened anyway, even if AEDs were continued. In fact, the nonrandomized and noncontrolled cohorts reported to date represent, by definition, a biased sample in which both physicians and patients felt comfortable enough to attempt AED withdrawal (typically after at least 1 to 2 years from surgery). These selected cohorts ultimately had low overall rates of seizure relapses (12% in Boshuisen et al., for example) underpowering any meaningful noninferiority analyses, and ironically then compromising “reassuring” conclusions about the long-term safety of attempting AED withdrawal.

In summary, the “stress test” hypothesis may be correct, but until it is unequivocally proven, the current situation of clinical equipoise will continue, and thoughtful retrospective studies like the manuscript at hand will be precious contributions. This commentary will not be the first call for a randomized clinical trial (RCT) to resolve these challenging questions, and while the research funding agencies contemplate the financial cost of such an RCT, patients and society will continue paying the exponentially bigger financial and psychosocial costs of unnecessary AED polytherapy and its complications.

by Lara Jehi, M.D.

References


Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 06/13/12

2. First Name Lara Last Name Jehi Degree MD

3. Are you the Main Assigned Author? ☒ Yes ☐ No

  If no, enter your name as co-author:

4. Manuscript/Article Title: The role of EEG after cardiac arrest and hypothermia AND Medication Management after Epilepsy Surgery: Opinions versus Facts.

5. Journal Issue you are submitting for: 13.4

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.
Section #3 Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ No other relationships/conditions/circumstances that present a potential conflict of interest.
☒ Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board